Oculis, an Icelandic life sciences company, just announced a $20.3m (20m CHF) series B round led by a syndicate of leading life science venture funds including Bay City Capital, Novartis Venture Fund and Pivotal bioVenture Partners. Existing investors, including Brunnur Ventures and Silfurberg, also participated in the financing. “I am extremely pleased to be joining such … Continue reading Oculis raises $20.3m Series B round to advance treatment for Ophthalmic Diseases